Miami Cardiovascular Innovations is a privately-held emerging company headquartered in Miami, Florida and engaged in the development of cardiovascular technologies. The Company was founded in March 2006 by Frank Avellanet and Ed de Marchena to design, develop, manufacture and market medical devices for the treatment of cardiovascular disorders. The company's initial focus is the treatment of coronary and vascular disease, a debilitating disorder affecting approximately 2.5 million people worldwide.
The Company’s approach to product development is to combine clinical medicine, molecular biology and biomedical engineering in order to develop biologically engineered medical products. Through this interdisciplinary approach, the present Company focus is to develop the next-generation of coronary and peripheral stents.
To be a leader in the development of cardiovascular diagnostic and therapeutic devices with a special focus on the next generation of products which merge clinical medicine, vascular biology and biomedical engineering.